Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verapamil in Preclinical Type 1 Diabetes (VIP-1)
NCT07880769Phase 3Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2027
- Primary completion
- Mar 2031
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing verapamil with Placebo (2 arms). Primary endpoint: Beta-cell function index at 48 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
verapamil
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07880769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07880769.